Huntington disease

Last updated: May 20, 2023

Huntington disease

Neuro

Neuro

Bones of the cranium
Anatomy of the cranial base
Anatomy of the cerebral cortex
Introduction to the cranial nerves
Cranial nerve pathways
Anatomy of the olfactory (CN I) and optic (CN II) nerves
Anatomy of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Anatomy of the trigeminal nerve (CN V)
Anatomy of the facial nerve (CN VII)
Ascending and descending spinal tracts
Cerebral circulation
Nervous system anatomy and physiology
Cranial nerves
Motor cortex
Pyramidal and extrapyramidal tracts
Muscle spindles and golgi tendon organs
Spinal cord reflexes
Sensory receptor function
Somatosensory receptors
Somatosensory pathways
Sympathetic nervous system
Parasympathetic nervous system
Adrenergic receptors
Cholinergic receptors
Cerebellum
Basal ganglia: Direct and indirect pathway of movement
Transient ischemic attack
Ischemic stroke
Intracerebral hemorrhage
Subdural hematoma
Epidural hematoma
Subarachnoid hemorrhage
Arteriovenous malformation
Saccular aneurysm
Broca aphasia
Wernicke aphasia
Concussion and traumatic brain injury
Seizures and epilepsy
Febrile seizure
Cavernous sinus thrombosis
Alzheimer disease
Frontotemporal dementia
Creutzfeldt-Jakob disease
Vascular dementia
Dementia with Lewy bodies
Normal pressure hydrocephalus
Torticollis
Restless legs syndrome
Huntington disease
Essential tremor
Parkinson disease
Multiple sclerosis
Acute disseminated encephalomyelitis
JC virus (Progressive multifocal leukoencephalopathy)
Transverse myelitis
Central pontine myelinolysis
Brain herniation
Seizures: Pathology review
Traumatic brain injury: Pathology review
Dementia: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Cerebral vascular disease: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Benzodiazepines
Anti-parkinson medications
Anatomy of the eye
Anatomy and physiology of the eye
Photoreception
Optic pathways and visual fields
Anatomy and physiology of the ear
Vestibular transduction
Auditory transduction and pathways
Vestibulo-ocular reflex and nystagmus
Cortical blindness
Bitemporal hemianopsia
Cataract
Glaucoma
Retinal detachment
Age-related macular degeneration
Diabetic retinopathy
Corneal ulcer
Uveitis
Keratitis
Conjunctivitis
Hemianopsia
Homonymous hemianopsia
Conductive hearing loss
Tympanic membrane perforation
Otitis externa
Otitis media
Eustachian tube dysfunction
Vertigo
Meniere disease
Labyrinthitis
Acoustic neuroma (schwannoma)
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Vertigo: Pathology review

Transcript

Watch video only

Huntington disease, or HD, is a rare neurodegenerative disease that involves a repeated sequence of DNA that causes an abnormal protein to form, leading to abnormal movements and cognitive problems.

Huntington disease is an autosomal dominant genetic disorder, which means that one affected copy of a gene is enough to cause disease. Affected people are typically present in each generation, because an affected person (male or female) has a 50% chance of passing on the affected gene to a child, which causes that child to have the disease.

In most people, a gene called huntingtin or HTT on chromosome 4, contains a triplet repeat, where the nucleotides C, A, and G are repeated 10-35 times in a row. In people with Huntington disease, this repeat goes on for 36 or more times in a row. CAG codes for the amino acid glutamine, so people with Huntington disease patients will have 36 or more glutamines in a row in the huntingtin protein. So, in addition to being a triplet repeat disorder, HD is, more specifically, a “polyglutamine” disease.

The specific way in which extra glutamines cause HD symptoms isn’t fully worked out, but some clues are that the mutated protein aggregates within the neuronal cells of the caudate and putamen of the basal ganglia causing neuronal cell death. Cell death might be related to excitotoxicity – which is excessive signaling of these neurons, which leads to high intracellular calcium.

The expanded CAG repeats not only affect the huntingtin protein – they affect DNA replication itself. When copying the HTT gene, DNA polymerase can basically lose track of which CAG it’s on and accidently add extra CAGs. Since as a zygote develops into a fetus and eventually into a full adult, by the time sperm and eggs are created, several dozen cell divisions, each with a round of DNA replication have taken place, and so there have already been ample opportunities for repeat expansion, and the more repeats that’re added, the more unstable it gets.

This expansion of the originally inherited gene means a child of a parent with HD can inherit even more CAG repeats than the parent did. The higher the number of repeats in the protein, the earlier the age when a person starts having symptoms. This phenomenon is called anticipation, which means that Huntington disease families often show earlier symptom onset with each generation. Even repeats of 27-35 CAGs can expand occasionally; these are called “pre-mutation” alleles, since they don’t cause the disease, but they’re set-up for developing a mutation of 36 or more CAGs.

This process of adding more repeats is called repeat expansion and it happens way more in the production of sperm than of eggs, so both anticipation and new disease alleles generally happens when the father is the affected parent. When a person has 40+ repeats, they show 100% penetrance and they will have the disease. For reasons that remain unknown, people with 36-39 repeats can show reduced penetrance; some may have symptoms while others may not. Because of this penetrance, the test for HD, which counts the number of CAG repeats, is really good at determining whether HD will develop in an at-risk individual.